Vet Evid. 2023 Sep 15;8(3):vetevid-8-3-666. doi: 10.18849/ve.v8i3.666. eCollection 2023 Jul-Sep.
ABSTRACT
PICO QUESTION: In symptomatic cats with feline immunodeficiency virus (FIV), does high-dose subcutaneous recombinant feline interferon-omega (rFeIFN-ω) administration lead to reduced clinical signs compared to cats who were not administered rFeIFN-ω?
CATEGORY OF RESEARCH: Treatment.
NUMBER AND TYPE OF STUDY DESIGNS REVIEWED: Three studies were critically reviewed, including one randomised controlled trial, one non-randomised controlled trial, and one uncontrolled clinical trial.
STRENGTH OF EVIDENCE: Weak.
OUTCOMES REPORTED: Each of the studies reported that rFeIFN-ω administration significantly reduced clinical signs in FIV infected cats. However, all three papers have limitations in their study design and statistical analysis which lower the strength of the evidence they provide.
CONCLUSION: There is only weak evidence demonstrating that rFeIFN-ω administration leads to reduced clinical signs in FIV positive cats. Currently, there is a lack of well-designed, double-blinded, randomised, placebo-controlled clinical trials which have an adequate sample size and specifically focus on FIV positive cats. As a result, more robust evidence is needed to prove the definitive therapeutic benefit of rFeIFN-ω in symptomatic FIV patients. Treatment with rFeIFN-ω may still be considered by clinicians for cats with clinical signs potentially associated with retroviral infection, such as oral lesions and stomatitis, particularly if they are not responding well to supportive therapy alone.
PMID:42007441 | PMC:PMC13011114 | DOI:10.18849/ve.v8i3.666
